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Abstract
Background: Porcine reproductive and respiratory syndrome virus (PRRSV) is one of the most important pathogens
in the swine industry and causes important economic losses. No effective antiviral drugs against it are commercially
available. We recently reported that the culture supernatant of Actinobacillus pleuropneumoniae, the porcine
pleuropneumonia causative agent, has an antiviral activity in vitro against PRRSV in SJPL cells. Objectives of this
study were (i) to identify the mechanism behind the antiviral activity displayed by A. pleuropneumoniae and (ii) to
characterize the active molecules present in the bacterial culture supernatant.
Methods: Antibody microarray analysis was used in order to point out cellular pathways modulated by the
A. pleuropneumoniae supernatant. Subsequent, flow cytometry analysis and cell cycle inhibitors were used to
confirm antibody microarray data and to link them to the antiviral activity of the A. pleuropneumoniae supernatant.
Finally, A. pleuropneumoniae supernatant characterization was partially achieved using mass spectrometry.
Results: Using antibody microarray, we observed modulations in G2/M-phase cell cycle regulation pathway when
SJPL cells were treated with A. pleuropneumoniae culture supernatant. These modulations were confirmed by a
cell cycle arrest at the G2/M-phase when cells were treated with the A. pleuropneumoniae culture supernatant.
Furthermore, two G2/M-phase cell cycle inhibitors demonstrated the ability to inhibit PRRSV infection, indicating a
potential key role for PRRSV infection. Finally, mass spectrometry lead to identify two molecules (m/z 515.2 and
m/z 663.6) present only in the culture supernatant.
Conclusions: We demonstrated for the first time that A. pleuropneumoniae is able to disrupt SJPL cell cycle
resulting in inhibitory activity against PRRSV. Furthermore, two putative molecules were identified from the culture
supernatant. This study highlighted the cell cycle importance for PRRSV and will allow the development of new
prophylactic or therapeutic approaches against PRRSV.
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Background
Coinfections are likely more frequent in farm than re-
ported and it is well established that a primary infection
with a pathogen, viral or bacterial, may enhance the
infectious potential of a secondary pathogen [1–4]. The
porcine respiratory disease complex (PRDC) is a multi-
factorial disease affecting fattening pigs that is caused by
coinfections with viral and/or bacterial pathogens in-
cluding the porcine reproductive and respiratory syn-
drome virus (PRRSV), Actinobacillus pleuropneumoniae
and others [2, 5, 6]. PRDC is the most common disease
in swine industry resulting in significant economic losses
and is characterized by several symptoms including re-
spiratory distress, fever, lethargy, stunted growth and
death [2, 5, 6].
Coinfections are often studied by observing clinical
symptoms in model animals; however, the basic mecha-
nisms involved in these pathogen-pathogen interactions
are often overlooked. In vitro investigations can provide
insights for understanding coinfections. Our laboratory
recently developed a model to study co-infections by A.
pleuropneumoniae and PRRSV using SJPL cells [7].
PRRSV is a member of the Arteriviridae family and
Nidovirales order. It is an enveloped, single-stranded
positive sense RNA virus [8, 9]. The genome is approxi-
mately 15 kb in length and contains 11 open reading
frames (ORF) [10–12]. PRRSV can infect pigs and trigger
several symptoms (i.e. fever, inappetence, cyanosis),
reproductive disorders (i.e. abortion, stillborn piglets,
mummified fetuses) and respiratory disorders (i.e. cough,
hyperpnea, dyspnea) [13–15]. Furthermore, PRRSV is
the most important pathogen in swine production,
causes important economic losses, and no effective anti-
viral drugs against it are commercially available [16].
Actinobacillus pleuropneumoniae (App) is the causative
agent of porcine pleuropneumonia, an important disease
in swine industry. The disease is well controlled in USA
and Canada but still a significant problem in Latin
America and some Asian and European countries [17].
Actinobacillus pleuropneumoniae is a Gram-negative rod-
shaped bacteria and member of the Pasteurellaceae family.
This bacterium is known to possess many virulence
factors including lipopolysaccharides, capsular polysaccha-
rides, outer membrane proteins involved in the acquisition
of essential nutrients, surface molecules involved in
adherence to the respiratory tract and Apx toxins [18].
For a recent review about virulence factors of A. pleurop-
neumoniae see Chiers and collaborators [18].
We recently reported that A. pleuropneumoniae cul-
ture supernatant has an antiviral activity against PRRSV
in vitro in SJPL infected cells and in porcine alveolar
macrophages [7]. This antiviral activity is not induced by
A. pleuropneumoniae lipopolysaccharides or by pepti-
doglycan fragments (i.e. NOD1 and NOD2 ligands) [7].
The identity of the molecules responsible for the anti-
viral activity are unknown and their identification could
provide the basis for the development of new thera-
peutic drugs, including prophylactic drugs with suitable
biopharmaceutical properties against PRRSV infection. It
is of note that experiments performed with culture
supernatant of Haemophilus parasuis (strain Nagasaki),
a close relative of A. pleuropneumoniae, did not show
any antiviral activity against PRRSV (J. Labrie and M.
Jacques, unpublished data).
We hypothesize that the culture supernatant of A. pleur-
opneumoniae induces a specific SJPL cell response which
has an antiviral activity against PRRSV. The first objective
of the present study was to identify the mechanism behind
the antiviral activity displayed by A. pleuropneumoniae.
The second objective was to identify the molecules
present in the A. pleuropneumoniae culture supernatant
which are responsible for the antiviral activity against
PRRSV. Therefore, we first used an antibody microarray
to identify cell pathways modulated by the A. pleuropneu-
moniae culture supernatant, observed modulations in cell
cycle regulation pathways and confirm these modulations
by cell cycle analysis using flow cytometry. We also dem-
onstrated the ability of two known cell cycle inhibitors to
inhibit PRRSV. Finally, mass spectrometry was used to
detect and identify two molecules present only in the
culture supernatant of A. pleuropneumoniae.
Results
Protein profiling of SJPL cells
Lévesque and collaborators recently demonstrated that
both AppΔapxICΔapxIIC culture supernatant and
its ≤ 3 kDa ultrafiltrate have an antiviral activity in vitro
against PRRSV [7]. Therefore, protein profiling of SJPL
cells infected or not with PRRSV (MOI 0.5) and/or treated
or not with the AppΔapxICΔapxIIC culture supernatant
was performed using Kinex KAM-850 antibody micro-
array. Eight hundred and fifty four cell signaling proteins
were targeted, using 337 phosphosite-specific antibodies
and 517 pan-specific antibodies. Pan-specific antibodies
targeted both phosphorylated and unphosphorylated pro-
teins forms. Proteins were classified into nine groups ac-
cording to their cellular functions: (1) transcription and
translation factors; (2) proteins implicated in signal trans-
duction pathway; (3) proteins implicated in host-pathogen
interaction or in immune response; (4) proteins implicated
in stress response; (5) proteins implicated in cell spread-
ing, cell migration, cell survival, cell growth, cell cycle and
cell proliferation; (6) apoptosis signaling pathway; (7)
cytoskeleton-associated proteins; (8) proteins implicated
in cell biosynthesis and metabolism; (9) proteins impli-
cated in other biological process or unclassifiable proteins.
Data are expressed in percent of change from control
(mock-infected and untreated SJPL cells; % CFC) and are
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presented in Fig. 1 and Additional file 1: Table S1. The
AppΔapxICΔapxIIC culture supernatant upregulates in-
hibitor of nuclear factor kappa-B kinase subunit beta
(IKKβ), receptor-interacting serine/threonine-protein kin-
ase 2 (Rip2) and caspase-9 (CASP9). In cells treated with
AppΔapxICΔapxIIC culture supernatant, cell cycle regula-
tion proteins (M-phase inducer phosphatase 3 inactive
form (CDC25c (ser216)) and cyclin-dependent kinase 1/2
active forms (CDK1/2 (tyr161))) and caspase-3 (CASP3)
were modulated by the culture supernatant regardless of
whether they were infected with PRRSV or not. Also,
PRRSV seems to upregulate mitogen-activated protein kin-
ase (MAPK)/mitogen activated protein kinase ERK path-
way and NF-κB pathway. Indeed, serine/threonine-protein
kinase A-Raf (Raf-A), ERK1/2, interleukin-1 receptor-
associated kinase 4 (IRAK4) and cyclic AMP-responsive
element-binding protein 1 (CREB1) were differentially
modulated in presence or absence of culture supernatant.
Thus, PRRSV upregulates MAPK/ERK and NF-κB path-
ways. The culture supernatant seems to decrease the
PRRSV induced upregulation for MAPK/ERK and NF-κB
pathways. Overall, the antibodies microarray data suggests
that A. pleuropneumoniae culture supernatant modulates
SJPL cell cycle.
Effect of the AppΔapxICΔapxIIC culture supernatant on
cell cycle
The microarray antibodies data suggesting that
AppΔapxICΔapxIIC culture supernatant modulates SJPL
cell cycle, we decided to analyze SJPL and MARC-145 cell
cycle after an 18 h treatment with the AppΔapxICΔapxIIC
culture supernatant, using flow cytometry. SJPL cells
incubated in DMEM were used as normal cell cycle and
we obtained a mean 50.6 % of SJPL cells in Gap-1 phase
(G1-phase); 35.1 % of SJPL cells in DNA-synthesis phase
(S-phase); and 14.3 % of SJPL cells in Gap-2 and mitotic
phase (G2/M-phase) (Fig. 2a and b). We then used as
controls, two molecules known to modulate the cell cycle
at different phases. Nocodazole interferes with the
polymerization of microtubules, blocking treated cells in
G2/M-phase and inducing cell death by apoptosis [19].
Aphidicolin is a DNA-polymerase inhibitor and induces
cell cycle arrest in S-phase [20]. When SJPL cells were
treated with nocodazole or aphidicolin, we observed
Fig. 1 AppΔapxICΔapxIIC culture supernatant upregulated cellular proteins when SJPL cells were infected or not with PRRSV. Proteins represented
were selected using a Z-score difference (Z-score SJPL – Z-score SJPL treated/infected cells) threshold of plus 75 % (corresponding in log2 to 1.68 fold
change versus the control). CDC25c: ser216 phosphorylated form; CDK1/2: tyr161 phosphorylated form; Tau: ser516 and ser519 phosphorylated forms;
Rb: ser807 and ser811 phosphorylated forms
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differences between treated and untreated cells (Fig. 2a).
With nocodazole treatment, SJPL cell number in G2/M-
phase increased (in mean) to 41.5% and an additional
apoptotic peak before the G1-phase peak was seen as ex-
pected (Fig. 2a). With aphidicolin treatment, the propor-
tion of SJPL cells in S-phase increased (in mean) to 51.9 %
(Fig. 2a). Following validation with cell cycle controls,
SJPL cells were treated with the AppΔapxICΔapxIIC cul-
ture supernatant and significant variations in SJPL cell
cycle proportions (n = 15; P ≤ 0.001) were observed. On
average, proportion of SJPL cells in G1-phase stayed the
same as untreated cells (45.0 %). However, the proportion
of SJPL cells in S-phase and in G2/M-phase significantly
(n = 15; P ≤ 0.001) decreased to 21.1 % and increased to
Fig. 2 AppΔapxICΔapxIIC culture supernatant blocks SJPL cell cycle in G2/M-phase but not MARC-145 cell cycle. a Representative experiment of
SJPL and MARC-145 cell cycle profile analysis; DMEM, nocodazole and aphidicolin as controls are compared to the A. pleuropneumoniae culture
supernatant. G1: Gap-1 phase; S: synthesis phase; G2/M: Gap-2 and mitotic phases. b Distribution of cell cycle phases after SJPL cells treatments
with DMEM or AppΔapxICΔapxIIC culture supernatant. The experiments were repeated at least 4 times. Asterisks indicated significant differences
between untreated cells and cells treated with AppΔapxICΔapxIIC culture supernatant. ***P ≤ 0.001, values are presented as ± standard error of
the mean (SEM)
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33.9 %, respectively (Fig. 2a and b), indicating that A.
pleuropneumoniae culture supernatant had an effect on
SJPL cell cycle.
Lévesque and collaborators reported that the antiviral
effect of AppΔapxICΔapxIIC culture supernatant against
PRRSV was not observed in MARC-145 infected cells
[7]. To provide supplemental insight of the impact of
cell cycle arrests caused by the A. pleuropneumoniae
culture supernatant on SJPL infected cells and on
PRRSV infection, we treated MARC-145 cells with the
AppΔapxICΔapxIIC culture supernatant and analyzed
their cell cycle. Cell cycle of untreated and uninfected
MARC-145 cell was similar to the SJPL cell cycle. Pro-
portion of MARC-145 cells in the three phases was: 50.5 %
(G1-phase), 40.7 % (S-phase) and 8.8 % (G2/M-phase)
(Fig. 2a and b). When cells were treated with nocodazole
or aphidicolin, an increase of the proportion of MARC-145
cells in G2/M-phase for nocodazole or in S-phase
and G2/M-phase for aphidicolin was observed (Fig. 2a).
In contrast to SJPL cells, when MARC-145 cells were
treated with the culture supernatant, no differences were
observed between treated and control cells (Fig. 2a and b).
Effect of the ≤ 3 kDa AppΔapxICΔapxIIC culture
supernatant ultrafiltrate on SJPL cell cycle
Knowing that AppΔapxICΔapxIIC culture supernatant
modulates SJPL cells cycle, we treated cells with the ≤ 3
kDa DMEM ultrafiltrate (as control) or the ≤ 3 kDa App-
ΔapxICΔapxIIC culture supernatant ultrafiltrate to know
if the ≤ 3 kDa fraction also modulates the SJPL cell cycle.
The ≤ 3 kDa AppΔapxICΔapxIIC culture supernatant ul-
trafiltrate significantly (n = 4; P ≤ 0.01) increased the
number of cells in G2/M-phase from 11.8 % to 22.1 %
(in mean) (Fig. 3a and b (left side)). Thus, the ≤ 3 kDa
AppΔapxICΔapxIIC culture supernatant ultrafiltrate
which possesses the antiviral activity against PRRSV also
modulates SJPL cell cycle. No modulation of the cell
cycle was also observed in MARC-145 cells treated with
the AppΔapxICΔapxIIC culture supernatant (Fig. 3a
and b right side). This suggests a potential link between
Fig. 3 The≤ 3 kDa AppΔapxICΔapxIIC ultrafiltrate is sufficient to block SJPL cell cycle in G2/M-phase. a Representative experiment of SJPL and
MARC-145 cell cycle profile analysis; ≤ 3 kDa DMEM ultrafiltrate as control is compared to the ≤ 3 kDa AppΔapxICΔapxIIC culture supernatant
ultrafiltrate. b Distribution of cell cycle phases after SJPL cells treatments with the≤ 3 kDa DMEM ultrafiltrate or the≤ 3 kDa AppΔapxICΔapxIIC
culture supernatant ultrafiltrate. The experiments were repeated at least 2 times. Asterisks indicated significant differences. **P≤ 0.01, values are
presented as ± SEM
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cell cycle arrest in G2/M-phase and antiviral activity
against PRRSV in SJPL cells.
Effect of DIM and SBE-13 on SJPL cell cycle
We have previously shown, using protein profiling, that
AppΔapxICΔapxIIC culture supernatant upregulates
CDC25c (ser216) and CDK1/2 (tyr161), both of which
are implicated in the G2/M cell cycle regulation path-
way. Two specific cell cycle inhibitors were used to ver-
ify whether cell cycle modulation induced by the culture
supernatant is due to CDC25c and/or CDK1/2. We first
used DIM which is a specific activator of cell cycle in-
hibitor serine/threonine-protein kinase (Chk2), Chk2 is
an inhibitor of CDC25 and leads to a cell cycle arrest in
G2/M-phase [21]. Then, we used SBE-13 which is a se-
lective inhibitor of cell cycle activator polo-kinase iso-
forms: PLK1, PLK2, PLK3 [22]. These proteins are
implicated in the G2/M-phase transition pathway; PLK1
is a CDC25c activator and CDC25c promotes the G2/
M-phase transition using cyclin-B/CDK1 complex. Both
DIM and SBE-13 treatments induced a SJPL cell cycle
modulation (Fig. 4). G1-phase of SJPL cells was not
modulated by DIM or SBE-13 (Fig. 4a and b). The num-
ber of cells in S-phase was significantly (n ≥ 6; P ≤ 0.001)
decreased (in mean) from 35.1 % to 17.7 % and to 3.6 %
by DIM and SBE-13 treatments, respectively (Fig. 4a
and c) and proportions of cells in G2/M-phase were
significantly (n ≥ 6; P ≤ 0.001) increased (in mean) from
14.3 % to 37.0 % and to 51.8 % by DIM and SBE-13
treatments, respectively as previously observed with A.
pleuropneumoniae culture supernatant (Fig. 4a and d).
Evaluation of SJPL cell proliferation
In order to confirm the cell cycle arrest we performed
cell counts as an indicator of cell proliferation. Cells
were counted before and after treatments and ratios be-
tween the second and the first counts were determined.
These ratios were then compared to untreated cells ratio
Fig. 4 Chk2 activator and PLK inhibitor are both mimics of the AppΔapxICΔapxIIC culture supernatant. a Representative experiment of
SJPL cell cycle profile analysis; DMEM and AppΔapxICΔapxIIC culture supernatant are compared to DIM (Chk2 activator) and SBE-13
(PLK inhibitor). b Percentage of cells in G1 phase. c Percentage of cells in S-phase. d Percentage of cells in G2/M-phases. The experiments
were repeated at least 6 times. Asterisks indicated significant differences between DMEM cells and treated cells. ***P ≤ 0.001, values are
presented as ± SEM
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(DMEM) or to the ≤ 3 kDa DMEM ultrafiltrate ratio
(Fig. 5a). We have previously shown that nocodazole
and aphidicolin blocks SJPL cell cycle (Fig. 2a, upper
panel) and decreases SJPL proliferation (Fig. 5a). Fur-
thermore, cells treated with the AppΔapxICΔapxIIC cul-
ture supernatant, DIM or SBE-13 showed significantly
(n = 8; P ≤ 0.05) less proliferation than cells treated with
DMEM. Same effect was observed between cells treated
with the ≤ 3 kDa DMEM ultrafiltrate and cells treated with
the ≤ 3 kDa AppΔapxICΔapxIIC culture supernatant ultra-
filtrate; from a fold change of 2.4 to 1.3 ( n = 8; P ≤ 0.01).
These data indicated that the AppΔapxICΔapxIIC culture
supernatant or the ≤ 3 kDa AppΔapxICΔapxIIC culture
supernatant ultrafiltrate significantly decreased SJPL cells
proliferation.
Detection of PRRSV in SJPL infected and treated cells
Knowing that the culture supernatant disrupts SJPL cell
cycle and decreases SJPL cell proliferation we were inter-
ested to see whether both cell cycle inhibitors, DIM and
SBE-13, can also block PRRSV infection in SJPL cells.
When SJPL cells were infected with PRRSV and treated
with the AppΔapxICΔapxIIC culture supernatant, an
antiviral activity was observed (Fig. 6) as previously re-
ported by Lévesque and collaborators [7]. When SJPL
infected cells were treated with DIM, no PRRSV was de-
tected; in contrast to DIM solvent control (Fig. 6).
Similar observations can be done for cells treated with
SBE-13 and SBE-13 solvent control (Fig. 6). Absence of
PRRSV in SJPL infected cells treated with DIM and
SBE-13 suggests an antiviral effect of these two cell cycle
inhibitors against PRRSV.
Mass spectrometry analysis
In order to identify the actives molecules present in the
AppΔapxICΔapxIIC culture supernatant, mass spectrom-
etry was used. Interestingly, mass spectrometry and
collision-induced dissociation can provide comprehensive
spectra allowing structural information to be derived with
assistance of bioinformatics. Thus, mass spectrometry was
used to analyze the ≤ 3 kDa AppΔapxICΔapxIIC culture
supernatant ultrafiltrate to detect, identify and characterize
active molecules. The ≤ 3 kDa DMEM and ≤ 3 kDa
AppΔapxICΔapxIIC culture supernatant ultrafiltrates were
fractionated using a simple salting-out liquid-liquid extrac-
tion in order to remove undesired inorganic molecules.
Supernatant were then analyzed in full scan positive ion
mode by LC-MS/MS and results are presented with a total
ion current chromatogram (TIC) (Fig. 7a). Both ≤ 3 kDa
DMEM ultrafiltrate and ≤ 3 kDa AppΔapxICΔapxIIC
culture supernatant ultrafiltrate were then compared
and two unique peaks were observed in the ≤ 3 kDa
AppΔapxICΔapxIIC culture supernatant ultrafiltrate
(Fig. 7a, black arrows). Full scan spectra and extracted ion
Fig. 5 SJPL cell proliferation is inhibited by DIM and SBE-13. Cell counts were carried out before and after treatments as proliferation indicator.
a Cells treated with nocodazole (known to induce apoptosis), aphidicolin, AppΔapxICΔapxIIC culture supernatant, DIM or SBE-13. b Cells treated
with the≤ 3 kDa AppΔapxICΔapxIIC culture supernatant ultrafiltrate is compared to the≤ 3 kDa DMEM ultrafiltrate. The experiments were
repeated at least 8 times. Asterisks indicated significant differences between DMEM cells or the ≤ 3 kDa DMEM ultrafiltrate and treated cells.
*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, values are presented as ± SEM
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chromatograms show the presence of two individual peaks
at mass to charge (m/z) 515.2 (Fig. 7b) and m/z of 663.6
(Fig. 7c). Product ion spectra for these two peaks were ac-
quired. At m/z 515.2, four ions were observed at m/z
160.6; 239.6; 328.6; 347.6, and six ions were observed for
m/z 663.6 at m/z 495.0; 496.11; 551.0; 552.0; 606.9; and
607.9. However, using in silico fragmentation predictor
and database search (e.g. METLIN) we did not succeed to
unequivocally identify these two molecules present in A.
pleuropneumoniae culture supernatant.
Separation of the ≤ 3 kDa AppΔapxICΔapxIIC culture
supernatant ultrafiltrate using thin-layer chromatography
In order to improve fractionation of the ≤ 3 kDa
AppΔapxICΔapxIIC culture supernatant ultrafiltrate and
test molecules activities, we separated the suspected ac-
tive ingredients using thin-layer chromatography and
compare results with standards run on the same chro-
matogram. Migrations were carried out using a chloro-
form/methanol mixture and were then read using UV-A.
We observed a distinctive spot (retention factor (Rf) = 0.52)
present in the ≤ 3 kDa AppΔapxICΔapxIIC culture super-
natant ultrafiltrate (Fig. 8). Interestingly, this distinctive
spot was also present in the ≤ 3 kDa culture supernatant
ultrafiltrate of two reference strains of A. pleuropneumo-
niae: L20 (serotype 5b) and S4074 (serotype 1) (Fig. 8).
TLC spot (Rf = 0.52) was excised and molecules were ex-
tracted with acetonitrile and then analyzed by LC-MS/MS.
TIC and extracted ion chromatogram (XIC) of the ≤ 3 kDa
AppΔapxICΔapxIIC culture supernatant ultrafiltrate TLC
spot (Rf = 0.52) possesses both unique peaks observed at
m/z 515.2 and m/z 663.6 (Fig. 9). Thus, peaks correspond-
ing to m/z 515.2 and 663.6 correspond to the additional
TLC spot present in the A. pleuropneumoniae culture
supernatant.
Discussion
Lévesque and collaborators recently reported an in vitro
antiviral activity of the A. pleuropneumoniae culture
supernatant against PRRSV in SJPL infected cells and in
porcine alveolar macrophages [7]. The objective of the
study presented here was to identify the mechanism be-
hind the antiviral activity displayed by A. pleuropneumo-
niae and to identify the active molecules present in A.
pleuropneumoniae culture supernatant.
In SJPL infected cells, we demonstrated that PRRSV
strongly upregulates mitogen-activated protein kinase
(MAPK)/ERK pathway using ERK1/2, RAF-A and CREB.
Our results are in agreement with Lee and Lee which dem-
onstrated an activation of ERK1/2 during PRRSV infection
[23] and with Han and collaborators which highlighted that
PRRSV induces degradation of CREB-binding protein
(CBP) [24]. In contrast, treatment of cells with A. pleurop-
neumoniae culture supernatant decreased the upregulation
of CREB1 and ERK1/2 induced by PRRSV demonstrating
that the A. pleuropneumoniae culture supernatant decrease
MAPK/ERK and NF-κB pathways upregulation induced by
PRRSV. This observation is interesting as it can partly
Fig. 6 Detection of PRRSV in SJPL infected and treated cells. Primary antibodies targeted the PRRSV N protein and were revealed by an anti-rabbit
antiserum FITC-conjugated antibody. Representative immunofluorescence pictures were acquired at 100 ×magnification
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explain the antiviral activity of the culture supernatant
against PRRSV and should be further investigated.
Peptidoglycan fragments can stimulate the nucleotide-
binding oligomerization domain (NOD) pathway [25, 26].
Following activation, NOD1 or NOD2 recruits RIP2 and
nuclear factor of kappa light polypeptide gene enhancer in
B-cells inhibitor alpha (IκBα), leading to NF-κB activation
[27]. Protein profiling indicated that only RIP2, a specific
NF-κB activator, was upregulated by the culture super-
natant in absence of PRRSV. The absence of NF-κB acti-
vation by A. pleuropneumoniae culture supernatant alone
is certainly puzzling, but Lévesque and collaborators
demonstrated that NOD pathway induction using pep-
tidoglycan fragments did not lead to an antiviral effect [7].
Our results confirm their observation.
Auger and collaborators demonstrated a differential
expression of NF-κB pathway in SJPL cells after 3 h of
infection with A. pleuropneumoniae serotype 1 (S4074)
[28]. In SJPL cells treated with A. pleuropneumoniae cul-
ture supernatant, we only observed a weak upregulation
of IKKβ. Auger and collaborators implicated the A.
pleuropneumoniae lipopolysaccharides in NF-κB pathway
activation [28]. Absence of NF-κB activation by the
culture supernatant cannot be explained because A.
Fig. 7 Differential comparison of ions present in DMEM or AppΔapxICΔapxIIC culture supernatant using LC-MS/MS. Samples were analyzed by
LC-MS/MS in full scan positive ion mode. a TIC of DMEM and AppΔapxICΔapxIIC culture supernatant. b XIC m/z 515.2. c XIC m/z 663.6. Black
arrows: additional peaks in the culture supernatant
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pleuropneumoniae lipopolysaccharides were not removed
from the culture supernatant. Conversely, PRRSV seems
to be able to activate the NF-κB pathway in SJPL cells, as
was already observed in MARC-145 and alveolar macro-
phages [29].
Apoptosis is an important cell process which can be
regulated by caspases proteins [30]. We observed that A.
pleuropneumoniae culture supernatant weakly regulates
CASP3 and CASP9. Apx toxins from A. pleuropneumo-
niae are known to induce apoptosis through activation
of c-Jun N-terminal kinase (JNK)/MAPK pathway and
CASP3 [31, 32], as using an Apx mutant prevent this in-
duction of JNK/MAPK pathway. Our results suggest that
A. pleuropneumoniae culture supernatant do not induce
apoptosis. We did not observe any peak corresponding
to apoptosis during cell cycle analysis (Figs. 2a and 3a).
These results were in agreement with Auger and collab-
orator, who carried out Western blot to detect CASP3
activation and concluded that A. pleuropneumoniae was
not inducing apoptosis in SJPL cells [28].
Cell proliferation is a tightly controlled process. Many
cell cycle checkpoints can be modulated to provoke cell
cycle arrest. The G2/M-phase checkpoint is activated
after DNA damages and provides opportunity to stop
and repair the damaged cells. To the best of our know-
ledge, the observed cell cycle arrest induced by A. pleur-
opneumoniae has never been reported before. However,
Aggregatibacter actinomycetemcomitans (formerly Acti-
nobacillus actinomycetemcomitans) was able to stop
growth and induce cell cycle arrest in G2/M-phase of
HeLa cells, by production of the cytolethal distending
toxin (CDT) [33, 34]. With regards to PRRSV, Sun and
collaborators demonstrated the ability of its non struc-
tural protein 11 to control the cell cycle and to induce a
cell cycle arrest in S-phase [35]. We demonstrated that
A. pleuropneumoniae culture supernatant is able to in-
duce a G2/M-phase cell cycle arrest in SJPL cells, result-
ing in decreased cell proliferation. Using CDC25c,
CDK1/2 and PLK inhibitors, we confirmed the protein
profiling results. DIM and SBE-13 are known to induce
a cell cycle arrest in G2/M-phase and both decreased
proliferation of SJPL cells. The cell cycle arrest induced
by A. pleuropneumoniae can be due to a CDC25c or
CDK1/2 inhibition. We will further investigate this path-
way using Western-blot analysis of regulation proteins.
We also studied the effect of the culture supernatant on
the MARC-145 cell line. Lévesque and collaborators have
shown that the culture supernatant of A. pleuropneumo-
niae has no antiviral effect in MARC-145 cells [7]. In
agreement with this finding, our cell cycle observations
demonstrated a differentiated effect of the culture super-
natant on SJPL and on MARC-145 cells. In SJPL cells, the
culture supernatant induced a cell cycle arrest in G2/M-
phase, whereas the same culture supernatant has no anti-
viral and no cell cycle effects on MARC-145 cells. Similar
effects were observed for cell proliferation and for the cell
cycle arrest induce by DIM and SBE-13. These differences
between SJPL and MARC-145 cells support our results in-
dicating that the culture supernatant inhibited PRRSV in
SJPL cells by inducing a G2/M-phase cell cycle arrest.
Using tandem mass spectrometry we have isolated and
identified two unique peaks (m/z 515 and m/z 663) from
the ≤ 3 kDa AppΔapxICΔapxIIC culture supernatant ultra-
filtrate. We were able to separate and purify the ≤ 3 kDa
AppΔapxICΔapxIIC culture supernatant ultrafiltrate using
TLC plates, and more interestingly, to recover the two
peaks after TLC spots extraction. Unfortunately, mass spec-
trometry fingerprinting did not lead to identification of
these molecules corresponding to these two peaks. In order
to obtain more information and to definitely identify active
molecules, we have to refine extraction protocols and to
obtain higher purity products in amounts compatible with
1H and 13C nuclei nuclear magnetic resonance (NMR).
Conclusions
We have demonstrated for the first time that A. pleurop-
neumoniae disrupts the SJPL cell cycle and prevents
Fig. 8 Migration of DMEM and culture supernatant of different strains
of A. pleuropneumoniae by TLC. Representation of the TLC plate after
migration and revelation under UV-A light. D: DMEM, as control;
1: AppΔapxICΔapxIIC culture supernatant; 2: A. pleuropneumoniae
(serotype 5b, strain L20) culture supernatant ; 3: A. pleuropneumoniae
(serotype 1, strain 4074) culture supernatant. Framed spots: spots of
interest (Rf = 0.52) that were analyzed by LC-MS/MS
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SJPL cell proliferation. We have also demonstrated the
importance of cell cycle in PRRSV infection. Further-
more, two putative molecules were identified from the
culture supernatant. It seems likely that these molecules
are responsible for the antiviral activity of A. pleuropneu-
moniae against PRRSV. We have to further investigate
these molecules in the hope that it will lead to the devel-
opment of a new antiviral drug against PRRSV.
Methods
Cell lines
All cell culture products were purchased from Gibco
(Life Technologies, Grand Island, NY, USA). SJPL cell
line [36] and MARC-145 cell line [37] are known to sup-
port PRRSV replication [38, 39]. SJPL cells were pro-
vided by R.G. Webster (St. Jude Children’s Hospital,
Memphis, TN, USA) and were historically defined as
porcine lung cells [36] but were later found to come
from monkey [40]. SJPL cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10 % (v/v) fetal bovine serum (FBS), 2 mM L-glutamine,
1 mM sodium pyruvate, 1 % (v/v) MEM non-essential
amino acid (NEAA) solution, 100 μg/mL streptomycin,
100 U/mL penicillin, 50 mg/L gentamicin and 2.5 mg/L
amphotericin B. MARC-145 cell line is a subclone of
African green monkey kidney cell line MA104 [38].
MARC-145 cells were grown in minimum essential
medium (MEM) supplemented with 10 % (v/v) FBS, 2
mM L-glutamine, 10 mM HEPES, 10 μg/mL strepto-
mycin, 10 U/mL penicillin and 2.5 mg/L amphotericin
B. Cells were cultured and infected at 37 °C in a 5 %
CO2 atmosphere.
Bacterial and viral strains
Actinobacillus pleuropneumoniae non-hemolytic and
non-cytotoxic MBHPP147 was kindly provided by Ruud
P.A.M. Segers (MSD Animal Health, Boxmeer, The
Netherlands). This strain is a mutant of the serotype 1
reference strain S4074 producing non-active ApxI and
ApxII toxins (AppΔapxICΔapxIIC) [41]. Bacteria was
grown at 37°C in brain heart infusion broth (BHI; Oxoid
Ltd., Basingstoke, Hampshire, England) or in BHI agar
Fig. 9 LC-MS/MS analyses of the molecules extracted from the TLC spot (Rf = 0.52). a TIC of the control TLC spot. b TIC of the TLC spot present in the
AppΔapxICΔapxIIC culture supernatant. c XIC m/z 515.2 of the AppΔapxICΔapxIIC culture supernatant TLC spot. d XIC m/z 663.6 of the AppΔapxICΔapxIIC
culture supernatant TLC spot. Unique and signature peaks at m/z 515.2 and 663.6 were observed exclusively into AppΔapxICΔapxIIC culture supernatant
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(Oxoid Ltd.) supplemented with 5 μg/mL or 15 μg/mL
of β-nicotinamide adenine dinucleotide (β-NAD; Sigma-
Aldrich, St Louis, MO, USA), respectively.
The PRRSV North American reference strain IAF-
Klop was used in this study. This strain is a genotype II
strain [42, 43].
Bacterial culture supernatant
Actinobacillus pleuropneumoniae culture supernatant
was prepared as recently described by Lévesque and
collaborators [7]. Briefly, an overnight culture of
AppΔapxICΔapxIIC was diluted into fresh BHI broth
and grown to an OD600 of 0.6. This culture was then di-
luted into DMEM medium, supplemented with 10 %
FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, 1 %
NEAA, to 1 × 106 CFU/mL and incubated overnight at
37 °C. Bacterial cells were centrifuged at 4,000 g for 20
min and the supernatant was harvested and passed
through a 0.22 μm filter (Sarstedt Inc., Newton, NC,
USA). Filter-sterilized supernatant was ultrafiltrated
through a 3 kDa membrane (Merck Millipore Ltd., Car-
rigtohill, Cork, Ireland). Resulting culture supernatant
ultrafiltrate and the filter-sterilized supernatant were
stored at −20°C up to 6 months. Supplemented DMEM
medium was also ultrafiltrated through a 3 kDa mem-
brane and used as a control.
Protein profiling of SJPL cells
Sample preparation was performed as described by Auger
and collaborators [28]. Briefly, a T25 flask (Sarstedt Inc.) of
confluent SJPL cells (0.5 × 106 cells) were infected or not
with IAF-Klop PRRSV strain for 4 h (multiplicity of infec-
tion (MOI): 0.5) and then treated with AppΔapxICΔapxIIC
culture supernatant or left untreated for 18 h. These condi-
tions are known to block PRRSV replication [7]. Cells were
washed twice with Dulbecco's phosphate-buffered saline
(DPBS; Life Technologies) and 500 μL of lysis buffer was
added (20 mM MOPS (pH 7.0; Sigma-Aldrich), 2 mM
EGTA (Sigma-Aldrich), 5 mM EDTA (Fisher Scientific,
Fair Lawn, NJ, USA), 30 mM sodium fluoride (Sigma-
Aldrich), 60 mM β-glycerophosphate (pH 7.2; Sigma-
Aldrich), 20 mM sodium pyrophosphate (Sigma-Aldrich), 1
mM sodium orthovanadate (Sigma-Aldrich), 1 % (v/v)
Triton X-100 (Sigma-Aldrich) and one protease inhibitor
cocktail tablet Complete Mini EDTA-free (Roche Diagnostics
GmbH, Mannheim, Germany), pH 7.2). Cells were re-
moved using a cell scraper (Nalge Nunc International,
Rochester, NY, USA) and transferred into a microcentri-
fuge tube on ice. Sonication was performed at 180 Joules
using an ultrasonic processor (Cole-Parmer, Vernin Hills,
IL, USA) in order to lyse the cells. Samples were then
ultracentrifuged at 90,000 g for 30 min in a Sorvall RC
M100 ultracentrifuge (Beckman Coulter, Mississauga, ON,
Canada). Protein concentration was determined on the
supernatant using Pierce BCA protein assay kit (Thermo
Fisher Scientific Inc., Rockford, IL, USA) and was adjusted
to 2 mg/mL. Samples were then analyzed using Kinex
KAM-850 antibody microarray (Kinexus Bioinformatics
Corporation, Vancouver, BC, Canada). Kinex KAM-850
antibody microarray includes 854 antibodies which
target different cell signaling pathways and included
517 pan-specific antibodies and 337 phosphosite-specific
antibodies. These include 466 antibodies against protein
kinase, 44 antibodies against protein phosphatase, 46 anti-
bodies against stress response proteins, 75 antibodies
against protein implicated in transcription and 223 others.
Data were expressed in a chemiluminescence signal ratio
versus the untreated cells. The percentage change from
control (% CFC) was calculated for each protein by div-
iding the treated condition Z-ratio by the control Z-scores
X 100 as described previously [44].
Cell cycle analysis
Cell cycle analysis was done using a modified protocol
from Sazer and Sherwood [45]. Briefly, 0.5 × 106 SJPL
cells were cultured overnight in T75 flask (Sarstedt Inc.)
in DMEM. Cells were treated for 18 h at 37 °C in a 5 %
CO2 atmosphere with either DMEM, the ≤ 3 kDa
DMEM ultrafiltrate, AppΔapxICΔapxIIC undiluted culture
supernatant, the ≤ 3 kDa culture supernatant ultrafiltrate,
0.4 μM nocodazole (Sigma-Aldrich), 7.4 μM aphidicolin
(Sigma-Aldrich), 100 μM 3,3′-diindolylmethane (DIM;
R&D Systems Inc., Minneapolis, MN, USA) or 50 μM
SBE-13 hydrochloride (SBE-13; Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA). Cells were washed twice with
DPBS and then trypsinized at 37 °C for 10 min. Trypsin
(Life Technologies) was inhibited using complete medium
and cells were centrifuged at 380 g for 15 min at 4 °C. Cells
were washed one more time with DPBS and then fixed and
permeabilized using 70 % (v/v) cold ethanol for 2 h at
room temperature followed by an overnight incubation at
4 °C. Cells were washed twice with DPBS then treated for
2 h at 37 °C with 2 mg of ribonuclease-A (RNase-A;
Sigma-Aldrich) in 900 μL of DPBS and cells were finally
stained with 100 μL of propidium iodide (PI) 0.2 mg/mL
(Sigma-Aldrich). Stained cells were analyzed on BD FACS
Calibur (Becton Dickinson, Mississauga, ON, Canada),
measuring fluorescence emission at 585 nm after excitation
at 488 nm. For each analysis, 10,000 events were evaluated
and DNA content was determined by ModFit LT v3.0
(Verity software house Inc., Topsham, ME, USA), which
provided histograms to evaluate cell cycle distribution.
Cell counting
To compare cell proliferation and cell viability during
treatments, we used a Countess automated cell counter
(Life Technologies). After the trypsinization step in the
cell cycle analysis protocol, cells were washed twice in
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DPBS and centrifuged at 380 g for 15 min at 4 °C. Cells
were resuspended into 1 mL DPBS and 100 μL of this
cell suspension was added to 100 μL of trypan blue (Life
Technologies) and 10 μL of this dilution was added to a
Countess cell counting chamber slide (Life Technologies)
to perform cells count and viability measurement.
Data were automatically expressed as number of
viable cells per mL.
Immunofluorescence assay
To detect PRRSV infected cells, we used a modified im-
munofluorescence assay (IF) protocol from Provost and
collaborators which detects PRRSV antigens [39]. Briefly,
confluent cells (1 × 104 cells per well in 96-well plates
(Corning Inc., Corning, NY, USA)) were infected or not
with PRRSV (MOI: 0.5) for 4 h and treated for 44 h with
either DMEM, the ≤ 3 kDa DMEM ultrafiltrate,
AppΔapxICΔapxIIC undiluted culture supernatant,
the ≤ 3 kDa culture supernatant ultrafiltrate, 100 μM
DIM, 0.25 % (v/v) ethanol (DIM solvent), 50 μM SBE-13
or 0.5 % (v/v) H2O (SBE-13 solvent). Following infection
and/or treatment, cells were washed and then fixed for 15
min at room temperature with a 50 % (v/v) methanol
(Fisher Scientific) and 50 % (v/v) acetone (J.T. Baker Inc.,
Phillipsburg, NJ, USA) solution. Cells were washed three
times using phosphate-buffered saline without KCl (PBS):
0.1 M NaCl (Sigma-Aldrich), 4 mM Na2HPO4 (Fisher
Scientific), 1.5 mM KH2PO4 (Biopharm Inc., Laval, QC,
Canada) and then incubated for 90 min at 37 °C with a
rabbit monospecific antisera (anti-PRRSV N protein) [43],
diluted 1/150 in PBS. Cells were washed three times with
PBS and incubated at 37 °C for 60 min with an anti-rabbit
antiserum FITC-conjugated (Life Technologies) dilu-
ted 1/75 in PBS. Finally, cells were washed three
other times with PBS and visualized using a Leica
DMI 4000 inverted widefield fluorescence microscope
(Leica Microsystems Inc., Richmond Hill, Canada).
Pictures were acquired using DFC 490 digital camera
(Leica Microsystems Inc.) and images were analyzed
using Leica Application Suite Software, version 2.4.0
(Leica Microsystems Inc.).
Sample preparation for biochemical analysis
In order to eliminate salts and remove inorganic con-
taminants, a salting-out liquid-liquid extraction was per-
formed. Briefly, 2 mL of ultrafiltrate samples (≤3 kDa)
were mixed vigorously for 1 min with 2 g of NaCl (Sigma-
Aldrich) and 2 mL of acetonitrile (Fisher Scientific),
organic layer was kept after decantation for analysis.
Thin-layer chromatography
Thin-layer chromatography (TLC) plates were used to
analyze samples and preparative TLC plates were used
to isolate molecules of interest. For samples analysis,
40 μL of the ≤ 3 kDa ultrafiltrate were applied on a 5 cm×
10 cm (length × width) silica gel plate (Sigma-Aldrich).
For preparative TLC plates, 1 mL of the ≤ 3 kDa ultrafil-
trates were applied on a 20 cm× 20 cm (length × width)
silica gel plate (Sigma-Aldrich). Samples were separated
with a mobile phase composed of 75 % (v/v) chloroform
(BDH Inc., Toronto, Ontario, Canada) and 25 % (v/v)
methanol (Fisher Scientific) in a saturated-closed glass
chamber. Migration was performed at ambient tem-
perature (21 °C ± 3 °C). After migration, plates were air-
dried for 5 min and then observed under a ultra-violet A
(UV-A) light (Ultra-Lum Inc., Claremont, CA). Areas
which correspond to spots of interest were scraped from
the silica gel plate and transferred into a microcentrifuge
tube. The extracted silica was weighed and molecules were
extracted with acetonitrile at a ratio of 1:3 (w/v) for 2 h at
room temperature. Samples were then centrifuged at
18,000 g for 5 min and the supernatant was kept for liquid
chromatography tandem mass spectrometry (LC-MS/MS)
analysis.
Instrumentation and bioanalytical methods
The LC-MS/MS system included a Thermo Surveyor
autosampler, a Thermo Surveyor MS pump and a Thermo
LCQ Advantage Ion Trap Mass Spectrometer (Thermo
Scientific, San Jose, CA, USA). Data was acquired and
analyzed with Xcalibur 1.4 (Thermo Scientific). Samples
were analyzed by LC-MS/MS in full scan positive ion
mode. Briefly, 2 μL of sample was injected and the
separation was achieved with a gradient mobile phase
along with a microbore column Thermo Biobasic C8
(100 × 1 mm) (Thermo Scientific), with a particle size of 5
μm. The initial mobile phase condition consisted of aceto-
nitrile and water (both fortified with 0.4 % (v/v) of formic
acid) at a ratio of 5:95. From 0 to 1 min, the ratio was
maintained at 5:95. From 1 to 21 min, a linear gradient
was applied up to a ratio of 90:10 and maintained for
5 min. The mobile phase composition ratio was then
reverted to the initial conditions and the column was
allowed to re-equilibrate for 14 min for a total run time of
40 min. The flow rate was fixed at 75 μL/min. Mass spec-
trometer was coupled with the LC system using a pneu-
matically assisted electrospray ion source (ESI). Sheath
nitrogen gas was set to 10 units and ESI electrode was set
to 4000 V in positive mode. Capillary temperature was set
at 300 °C and capillary voltage to 34 V. Instrument was
operating in full scan MS mode (m/z 200–1000) and
MS/MS data was collected on the most abundant peaks
in a data dependent acquisition (DDA) mode using a peak
intensity threshold of 1 × 105 counts per second (cps).
The ≤ 3 kDa ultrafiltrate of DMEM was used as a negative
control and spectra were compared with the ≤ 3 kDa
ultrafiltrate of the A. pleuropneumoniae culture super-
natant or the TLC extracted molecules.
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Statistical analyses
For cell cycle data analyses, an arcsine square root
ASIN(SQRT(x)) transformation was performed before
statistical analysis. When n was equal or above eight, a
d’Agostino and Pearson omnibus normality test was then
utilized, followed by a one-way analysis of variance
(ANOVA) with Dunnett post-test or a paired t-test to
determine if significant differences exists between the
different cell cycle phases or the cell-counting results of
untreated and treated cells. All statistical analyses were per-
formed using GraphPad PRISM v5 (GraphPad Software
Inc., San Diego, CA, USA). Significant differences were
considered when P ≤ 0.05.
Additional file
Additional file 1: Protein profiling of SJPL cells after infection or
not with PRRSV for 4 h (MOI = 0.5) and/or treatment for 18 h with the
AppΔapxICΔapxIIC culture supernatant using the Kinex KAM-850
antibody microarray. (XLSX 48 kb)
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